Sanara MedTech Inc. (SMTI) Stock

Sanara MedTech Inc., based in Fort Worth, Texas, is a dynamic company dedicated to developing, marketing, and distributing advanced wound and skin care products across the United States. Catering to a wide spectrum of healthcare settings including physicians, hospitals, clinics, and post-acute care facilities, Sanara MedTech specializes in providing innovative solutions that promote effective patient healing.

Among its flagship offerings, Sanara MedTech features CellerateRX Surgical Activated Collagen in both powder and gel forms, widely used across various surgical specialties to accelerate the healing process. The company also markets Biako�s line of antimicrobial products, including an innovative cleanser and wound gel designed to combat both mature biofilm microbes and planktonic microbes, addressing critical challenges in wound care management.

Sanara MedTech further enhances its product portfolio with HYCOL Hydrolyzed Collagen, a medical-grade hydrolysate known for its efficacy in managing complex wounds such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. The company�s commitment to innovation is underscored by its development of advanced wound care devices like FORTIFY TRG and FORTIFY FLOWABLE, leveraging freeze-dried extracellular matrix technology to support tissue repair and regeneration.

Founded in 2001 and originally known as WNDM Medical Inc., Sanara MedTech rebranded in May 2019 to reflect its expanding focus and commitment to advancing wound care solutions. With a robust presence in the healthcare market, Sanara MedTech continues to pioneer new standards in wound management through its ongoing research, development, and strategic partnerships within the medical community.